A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1

被引：0
|
作者：
Oh, D-Y. [1 ]
Chen, L-T. [2 ]
He, A. R. [3 ]
Okusaka, T. [4 ]
Qin, S. [5 ]
Chin, S. [6 ]
Rokutanda, N. [6 ]
Uchinda, H. [7 ]
Vogel, A. [8 ]
Valle, J. W. [9 ]
Kim, H. [7 ]
机构：
[1] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea
[2] Natl Inst Canc Res, Natl Hlth Res Inst, Tainan, Taiwan
[3] Georgetown Univ, Med Ctr, Div Hematol & Oncol, Washington, DC 20007 USA
[4] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
[5] Peoples Liberat Army, Ctr Canc, Med Oncol, Nanjing, Jiangsu, Peoples R China
[6] AstraZeneca, Oncol, Gaithersburg, MD USA
[7] AstraZeneca KK, R&D, TA Div, Med Sci Dept Oncol, Osaka, Japan
[8] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[9] Univ Manchester, Christie NHS Fdn Trust, Inst Canc Sci, Med Oncol, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
831TiP
引用
收藏
页码：319 / 319
页数：1
相关论文
共 50 条
  • [1] A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
    Oh, Do-Youn
    He, Aiwu Ruth
    Qin, Shukui
    Chen, Li-Tzong
    Okusaka, Takuji
    Vogel, Arndt
    Kim, Jin Won
    Suksombooncharoen, Thatthan
    Lee, Myung Ah
    Kitano, Masayuki
    Burris, Howard A., III
    Bouattour, Mohamed
    Tanasanvimon, Suebpong
    Zaucha, Renata
    Avallone, Antonio
    Cundom, Juan
    Rokutanda, Nana
    Xiong, Julia
    Cohen, Gordon
    Valle, Juan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [2] Efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: Extension cohort of the phase III, randomised, double-blind, placebo-controlled, global TOPAZ-1 study
    Qin, S.
    Cai, J-Q.
    Li, E.
    Xing, B.
    Zhao, L.
    Dai, C.
    Li, J.
    Shen, Y.
    Chen, Z.
    Liu, L.
    Lu, Z.
    Zang, A.
    Bai, Y.
    Liang, H.
    Liang, J.
    Liu, X.
    Wang, J.
    Chen, M-H.
    Miao, R.
    Qu, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S216 - S217
  • [3] Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1)
    Choe, Jung Wan
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2023, 82 (02): : 105 - 106
  • [4] Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
    Burris, Howard A., III
    Okusaka, Takuji
    Vogel, Arndt
    Lee, Myung Ah
    Takahashi, Hidenori
    Breder, Valeriy
    Blanc, Jean-Frederic
    Li, Junhe
    Bachini, Melinda
    Zotkiewicz, Magdalena
    Abraham, Jayne
    Patel, Nikunj
    Wang, Julie
    Ali, Muzammil
    Rokutanda, Nana
    Cohen, Gordon
    Oh, Do-Youn
    LANCET ONCOLOGY, 2024, 25 (05): : 626 - 635
  • [5] Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
    Okusaka, T.
    Kitano, M.
    Chen, M-H.
    Chen, J-S.
    Ostwal, V. S.
    McNamara, M. G.
    Breder, V.
    Petrova, M.
    Buchschacher, G.
    Rokutanda, N.
    Xiong, J.
    Cohen, G.
    Oh, D-Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1471 - S1471
  • [6] Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
    He, A. R.
    Valle, J. W.
    Lee, C-K.
    Ikeda, M.
    Potemski, P.
    Morizane, C.
    Cundom, J. E.
    Tougeron, D.
    Dayyani, F.
    Rokutanda, N.
    Xiong, J.
    Cohen, G.
    Oh, D-Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1467 - S1468
  • [7] Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study
    Okusaka, T.
    Kitano, M.
    Chen, M.
    Chen, J.
    Ostwal, V.
    McNamara, M.
    Breder, V.
    Petrova, M.
    Buchschacher, G., Jr.
    Rokutanda, N.
    Xiong, J.
    Cohen, G.
    Oh, D.
    ANNALS OF ONCOLOGY, 2022, 33 : S242 - S242
  • [8] Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer
    Finkelmeier, Fabian
    Bouattour, Mohamed
    Valle, Juan
    Vogel, Arndt
    Kim, Jin Won
    Kitano, Masayuki
    Chen, Jen-Shi
    Burris, Howard
    Zaucha, Renata
    Qin, Shukui
    Evesque, Ludovic
    Zhen, David B.
    Gupta, Vineet Govinda
    Park, Joon Oh
    Zotkiewicz, Magdalena
    Rokutanda, Nana
    Cohen, Gordon
    Oh, Do-Youn
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 63 - 64
  • [9] Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study
    He, A.
    Valle, J.
    Lee, C.
    Ikeda, M.
    Potemski, P.
    Morizane, C.
    Cundom, J.
    Tougeron, D.
    Dayyani, F.
    Rokutanda, N.
    Xiong, J.
    Cohen, G.
    Oh, D.
    ANNALS OF ONCOLOGY, 2022, 33 : S378 - S378
  • [10] Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the Phase 3 TOPAZ-1 study
    Pelzer, U.
    He, A. R.
    Tan, B.
    Suksombooncharoen, T.
    Takahashi, H.
    Chen, M. -H.
    Ostwal, V.
    Oh, S. C.
    Sezer, E.
    Potemski, P.
    Rau, K. -M.
    Sirachainan, E.
    Li, J.
    Blanc, J. -F.
    Cohen, G.
    Zotkiewicz, M.
    Rokutanda, N.
    Oh, D. -Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 59 - 60
12345